Sandu Pharmaceuticals Ltd

BSE: 524703

29

total announcements

SANDUPHQ.BO · 15 min delayed

Key Stats · Yahoo Finance · as of 20 Nov 2026

Market Cap

₹36 Cr

P/E (TTM)

18.8

EPS (TTM)

₹1.96

52W Low

₹30.00

52W High

₹50.00

Dividend Yield

2.67%

Beta

0.37

Price / Book

0.8

Debt / Equity

1.0

Revenue (TTM)

₹70 Cr

Gross Margin

57.95%

Operating Margin

3.37%

BSECompany UpdateResults11 Aug 2026

Sandu Pharmaceuticals Ltd

Intimation about the date of the annual General Meeting

Sandu Pharmaceuticals Ltd has announced the date of its annual General Meeting to be held on September 11, 2026. The meeting will be conducted through Video Conferencing (VC)/Other Audio-Visual Means (OAVM). The company has also recommended the proposal for obtaining approval of the Members at the ensuing Annual General Meeting for the continuation of Material Related Party Transactions with M/s. Sandu Brothers Private Limited.

Read more →📎 1 attachment
BSECorp. ActionResults11 Aug 2026

Sandu Pharmaceuticals Ltd

Intimation about the Record date

Sandu Pharmaceuticals Ltd has announced the outcome of its Board Meeting held on August 11, 2026, where it approved the unaudited standalone financial results for the quarter ended June 30, 2026, and other business matters, including the record date for determining the eligibility of members entitled to receive the proposed dividend for the financial year ended March 31, 2026.

Read more →📎 1 attachment
BSECorp. ActionResults11 Aug 2026

Sandu Pharmaceuticals Ltd

Intimation about Book closure for AGM

Sandu Pharmaceuticals Ltd has announced the outcome of its Board Meeting held on August 11, 2026, where it approved the unaudited standalone financial results for the quarter ended June 30, 2026, and other business matters. The company has also announced the book closure for its AGM on September 4-11, 2026, and recommended the approval of material related party transactions with Sandu Brothers Private Limited.

Read more →📎 1 attachment
BSECompany UpdateResults11 Aug 2026

Sandu Pharmaceuticals Ltd

Outcome and results of the Board Meeting dated 11.08.2026

Sandu Pharmaceuticals Ltd announced its unaudited standalone financial results for the quarter ended June 30, 2026, which were approved by the Board of Directors. The company also approved the convening of its 41st Annual General Meeting to be held on September 11, 2026, through video conferencing. Additionally, the Board recommended the proposal for obtaining approval for material related party transactions with Sandu Brothers Private Limited and approved the appointment of Dave & Dave, Chartered Accountants as Statutory Auditors for a first term of five consecutive years.

Read more →📎 1 attachment
BSEResultResults11 Aug 2026

Sandu Pharmaceuticals Ltd

Unaudited Financials For ended 30.06.2026

Sandu Pharmaceuticals Ltd has announced unaudited financial results for the quarter ended June 30, 2026, with the board approving the results and recommending the appointment of new statutory auditors. The company also announced the convening of its 41st Annual General Meeting on September 11, 2026, and recommended the continuation of material related party transactions with Sandu Brothers Private Limited.

Read more →📎 1 attachment
BSECompany UpdateResults11 Aug 2026

Sandu Pharmaceuticals Ltd

Outcome of the Board Meeting 11.08.2026

Sandu Pharmaceuticals Ltd announced its unaudited standalone financial results for the quarter ended June 30, 2026, which were approved by the Board of Directors. The company also approved the convening of its 41st Annual General Meeting on September 11, 2026, and recommended the continuation of material related party transactions with Sandu Brothers Private Limited. Additionally, the Board approved the appointment of M/s. Dave & Dave, Chartered Accountants, as the Statutory Auditors of the Company for a first term of five consecutive years.

Read more →📎 1 attachment
BSEBoard MeetingResults11 Aug 2026

Sandu Pharmaceuticals Ltd

Outcome of the Board Meeting

Sandu Pharmaceuticals Ltd approved its unaudited standalone financial results for Q1 FY2026-27, with the board of directors taking note of the statement of utilisation and statement of deviation(s) in utilisation of funds for the quarter ended June 30, 2026. The company also approved the convening of its 41st Annual General Meeting on September 11, 2026, and recommended the proposal for obtaining approval of the members at the ensuing Annual General Meeting for the continuation of material related party transactions with M/s. Sandu Brothers Private Limited. Additionally, the board approved the appointment of M/s. Dave & Dave, Chartered Accountants, as statutory auditors of the company for a first term of five consecutive years.

Read more →📎 1 attachment
← PreviousPage 2 of 2